reason report
cheap enough yet fall short pipelin depend
bottom line last night gilead report result
produc first signific disappoint larg cap
biotech earn season total revenu fell well short
consensu estim
result gener weak across board hcv come
consensu
estim hiv come consensu
estim even biktarvi sale fell short
estim consensu prescript volum
convers sale fell short estim channel inventori
buy estim lower expect
estim consist high fail
incorpor increasingli acut reduct channel
inventori net price domin gilead result
undermin report sale estim sub-channel
inventori reduct cost gilead approxim hiv sale
us mainli obscur underli growth
sequenti hiv rx ex viread gilead yescarta result
beat consensu estim unlik
much comfort investor given disappoint result
rest compani portfolio
result revenu weak gilead ep also
fell short consensu expect estim
oper expens lower consensu expect
oper margin still came percentag
point lower consensu
estim gilead maintain prior financi
guidanc year mani analyst investor suspend
confid achiev revenu guidanc base upon
quarter result made substanti chang revenu
earn forecast cut revenu forecast
cut ep forecast
later year reduc
estim significantli recent consensu estim
expect forecast also reduc
averag price-to-earnings large-cap revenu
multipl slower-growth medic co
sum part exist franchis
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm non-gaap ep ex stock option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
base upon reduct estim chang
compar compani valuat reduc price target
reiter market perform rate gilead stock
stock start trade favor second half
year compani prognost outlook two core
busi correct assum profil filgotinib hold
read out phase ii phase trial
rate gilead stock market perform price target downgrad stock
sept chang hepat market forecast compani erod
sharpli sooner anticip specif see patient volum declin
steadili initi peak market revenu yield per patient continu trend
neg base decreas treatment durat increas discount manufactur
compet govern commerci contract posit forecast hcv sale declin
continu eros subsequ year due competit market
dynam outlook compani hiv busi remain posit suffici
off-set unusu dynam hcv busi rel modest contribut
product offer littl mitig effect boom bust hcv forecast total hcv
revenu fall short current consensu like drive signific
neg margin trend given hcv extrem strong profit hope gilead
intern develop pipelin busi develop invest could off-set risk
opportun appear arriv late littl valu high price
gilead manag miss sever attract transact opportun paid high
premium enter oncolog market cellular therapi without declar competit
advantag gilead valuat current all-tim low like recov rel peer
earn declin potenti continu neg revis substanti
termin uncertainti make hard us recommend stock
top-lin miss spread across multipl product amplifi discount inventori
drawdown total revenu well consensu
estim total hiv product sale consensu
estim miss driven inventori reduct hiv
product us eros viread due gener introduct decemb
channel inventori situat like compound launch biktarvi
presum share shift product distributor level largest miss matur hiv
product stribilid atripla us viread declin
initi period gener competit total hcv sale also significantli
consensu estim reflect eros market share
price due market entri abbvi mavyret sale non-antivir product letairi
ranexa ambisom yescarta report modest beat consensu estim
yescarta sale doubl consensu expect
bottom-lin pressur decreas margin gross margin
line consensu forecast gross margin fallen
sequenti non-gaap consensu
forecast non-gaap sg consensu
estim total gilead total expens consensu
estim gilead expens came consensu estim
reduct larg revenu shortfal oper margin
percentag point compar year ago percentag point
forecast effect tax rate consensu forecast
result pro-forma incom tax result non-gaap dilut ep
recent consensu estim compani net cash posit
remain although total cash declin total adjust debt
declin effect de-lever compani back debt
posit prior close kite acquisit last year
guidanc maintain februari clearli risk guidanc miss gilead
maintain previous issu financi guidanc gener mani question
compani confer call hcv sale come trend
investor question compani achiev inform hcv guidanc
year compani non-hcv sale guidanc would also seem risk
given non-hcv sale note compar product
sale guidanc recent consensu estim within
rang updat estim guidanc gilead also reiter
product gross margin manag believ trough year
impact top-lin shift away hcv sale higher margin product howev shift
partner hiv product atripla genvoya biktarvi help gross margin
long-term gilead also continu expect non-gaap sg expens
report effect tax rate note
item recent consensu estim within relev guidanc rang gross
margin guidanc still seem achiev sg trend annual
compani could deliv posit varianc save discretionari expens partial
off-set top-line weak overal despit maintain guidanc revenu trend would
appear favor compani current guidanc particularli sinc compani still absorb
loss exclus letairi mid-year annual close well
volum share price eros hcv
hcv market share declin volum share price slide base gilead
recent disclosur earn call well previous report sale
merck estim gilead new us patient start
averag forecast predict total us hcv start continu
decreas high singl digit percentag near term estim gilead share
us hcv market continu declin believ gilead revenu
per new patient start us ex-u materi
estim revenu per start us averag us
outsid us gilead revenu per start also declin substanti
high assum gilead correct us price environ
stabil introduct new lower price contract seem like us us
sale gilead hcv portfolio declin continu
declin high singl digit percentag rang sequenti quarter updat
forecast also estim gilead rate ex-u new start continu declin mid-high
singl digit percentag point rang revenu per start trend qoq
second half year result like sequenti declin trend ou sale
approxim throughout remaind year overal
revenu trend high report yesterday
hiv busi trend better result suggest amid lot head-scratch hand-
wring gilead result quarter confirm compani comment
strong underli busi trend despit report result correct post-hoc
analysi confirm ex-viread hiv rx volum grow compar
compar trend obscur estim
channel inventori reduct us quarter amount
headwind report sale reduct caus distributor buy product bulk
ahead inevit price increas compound mid quarter approv
launch biktarvi requir inventori prompt inventori
reduct legaci hiv combin medicin assum underli busi trend
prevail rather report financi perform us hiv sale could high
expect investor wait see result materi give
compani stock credit rebound confirm underli volum
trend appear line manag commentari
biggest pipelin event filgotinib selonsertib gilead manag
provid usual comprehens pipelin updat confer call gilead filgotinib
critic first phase rheumatoid arthriti readout finch biolog non-
respond gilead also announc pivot trial finch fulli
enrol compani add prior disclosur safeti toler re-
affirm posit lower effect platelet count filgotinib also reach futil analysi
ulcer coliti mid-year base endoscop endpoint week treatment-nav
biolog non-respond patient ra trial believ investor close examin
safeti result comparison upadacitinib lilli baricitinib especi regard
venou thromboembol event vte call gilead disclos phase ii
program patient year experi one vte event rate
per patient year compar per patient year inhibitor
baricitinib report latest fda adcomm see note bari adcomm mid-meet
report fda pushov sever phase ii filgotinib also read
year indic psoriat arthriti ankylos spondyl could support increment
revenu potenti product import result announc compani nash
program occur last quarter gilead disclos
week phase ii data fxr monotherapi importantli two separ monotherapi
phase studi selonsertib inhibitor fulli enrol fibrosi
patient read respect gilead plan file
simultan two studi close togeth near-term event
note approv yescarta biktarvi europ long-term follow-up yescarta
nhl initi data compani btk inhibitor r/r cll
leerink revenu earn estim cut consensu also come base
result quarter manag commentari well high-level analysi
current trend hcv model reduc revenu estim
long-term forecast gilead total revenu declin
begin grow declin due
lost exclus import hiv compon reduc total hcv revenu forecast
long-term also reduc total hiv revenu
forecast long-term revenu estim
consensu captur bullish bictegravir launch
ebit margin forecast percentag point
lower year reflect higher commerci spend guidanc lower gross margin
tax rate share count estim rel stabl near-term result pro forma ep
estim reduc
ep estim recent consensu
base chang revenu forecast ep estim cash
flow reduc price target gilead maintain market perform
rate gilead stock
price target inc base averag four approach
believ reason basi valu stock today approach trough
price earn multipl larg cap slow-growth medic product busi long term
revenu multipl larg cap medic product stock slow growth outlook sum
part valuat exist franchis discount cash flow dcf use trough consensu
forward earn multipl slow-growth medic product stock celg
sni appli ep estim gilead give price altern
appli slow-grow large-cap medic product us pharma spec pharma eu pharma
revenu multipl revenu estim deriv impli valu
impli one year price target use sum part valuat exist franchis
get price consist primarili price compani hiv franchis
hcv product lastli dcf use forecast free cash flow
appli growth rate termin cash flow forecast discount valu back
present wacc give present valu averag four approach
price target
risk view outlook valuat gilead includ major chang label
price reimburs coverag compani exist hiv hcv product emerg
aggress price discount rebat valu eros hiv hcv
categori current forecast failur compani princip pipelin
asset bictegravir hiv filgotinib ra ibd advanc develop
commerci opportun better perform valu expect includ
delay limit develop profil adopt competit hiv hcv
product success develop underappreci element compani portfolio
momelotinib selonsertib entospletinib stronger-than-expect convers current hiv
patient gilead next gener taf-bas hiv treatment regimen
royalti contract revenu
non-gaap cost good sold
share count period basic
guidanc
dilut ep impact relat acqusit
stock-bas compens
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time
follow data
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
million
darunavir/c/f-taf royalti
darunavir/c/f-taf royalti
leerink partner research compani file
million
sale incl emori amort
 total revenu
sg total revenu
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method trough price earn multipl larg cap slow growth biopharma compani
trough larg cap valu healthcar stock multipl ep sni
impli valuat ep
number period
equiti
method revenu multipl slow growth outlook larg cap biopharma stock appli
leerink revenu estim gilead
comp ex growth larg cap revenu multipl celg
impli valu gilead revenu
share outstand gilead
impli year price base revenu
method part valuat exist franchis kite
method dcf base current late stage pipelin product declin flow
wacc growth termin period
present valu late stage market product flow termin valu
net debt
present valu late stage market product flow
averag method
leerink partner research compani file factset
